Get the Stockscreener App
0.5585
7.01%
-0.0421
Pre-market:
.58
0.0215
+3.85%
Century Therapeutics Inc Stock (IPSC) Latest News
Century therapeutics officer sells shares worth $1,451 By Investing.com - Investing.com Australia
Century therapeutics CEO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Century therapeutics CEO sells shares to cover tax obligations - Investing.com
Century Therapeutics COO Farid Adrienne sells $1,450 in stock - Investing.com India
Century Therapeutics SVP sells $762 in stock - Investing.com
Century Therapeutics COO Farid Adrienne sells $1,450 in stock By Investing.com - Investing.com UK
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Century Therapeutics (IPSC) Expected to Announce Quarterly Earnings on Thursday - Defense World
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Century Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Century Therapeutics faces Nasdaq delisting over share price - Investing.com India
Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at 04:20 pm EST - Marketscreener.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Century Therapeutics CEO sells shares worth $27,179 - Investing.com
Century Therapeutics CEO sells shares worth $27,179 By Investing.com - Investing.com UK
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World
Leerink Partnrs Has Strong Forecast for IPSC FY2024 Earnings - Defense World
Brokers Offer Predictions for IPSC FY2029 Earnings - Defense World
FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs - MarketBeat
Ratios Reveal: Breaking Down Century Therapeutics Inc (IPSC)’s Financial Health - The Dwinnex
Quarterly Snapshot: Quick and Current Ratios for Janux Therapeutics Inc (JANX) - The Dwinnex
Analyzing Telephone And Data Systems, Inc (TDS) After Recent Trading Activity - Knox Daily
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Century Therapeutics COO Farid Adrienne sells $822 in stock - MSN
Century Therapeutics SVP sells shares worth $273 to cover taxes - MSN
Century Therapeutics COO Farid Adrienne sells $822 in stock By Investing.com - Investing.com Canada
Century Therapeutics SVP sells shares worth $273 to cover taxes By Investing.com - Investing.com Canada
New developments in autoimmune diseases - The Pharma Letter
Financial Metrics Exploration: Understanding Century Therapeutics Inc (IPSC) Through Ratios - The Dwinnex
JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):